237 related articles for article (PubMed ID: 23585851)
1. Galectin-9 ameliorates clinical severity of MRL/lpr lupus-prone mice by inducing plasma cell apoptosis independently of Tim-3.
Moritoki M; Kadowaki T; Niki T; Nakano D; Soma G; Mori H; Kobara H; Masaki T; Kohno M; Hirashima M
PLoS One; 2013; 8(4):e60807. PubMed ID: 23585851
[TBL] [Abstract][Full Text] [Related]
2. Effect of nonmyeloablative unrelated fetal and neonatal murine peripheral blood mononuclear cell infusion on MRL/lpr mice.
Chuan W; Wu-qing W; Zhu-wen Y; Zuo L
Lupus; 2014 Sep; 23(10):994-1005. PubMed ID: 24756437
[TBL] [Abstract][Full Text] [Related]
3. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
Hou LF; He SJ; Li X; Yang Y; He PL; Zhou Y; Zhu FH; Yang YF; Li Y; Tang W; Zuo JP
Arthritis Rheum; 2011 Aug; 63(8):2445-55. PubMed ID: 21484768
[TBL] [Abstract][Full Text] [Related]
4. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
Yan SX; Deng XM; Wang QT; Sun XJ; Wei W
Acta Pharmacol Sin; 2015 Nov; 36(11):1367-76. PubMed ID: 26456588
[TBL] [Abstract][Full Text] [Related]
5. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.
Shimp SK; Chafin CB; Regna NL; Hammond SE; Read MA; Caudell DL; Rylander M; Reilly CM
Cell Mol Immunol; 2012 May; 9(3):255-66. PubMed ID: 22543833
[TBL] [Abstract][Full Text] [Related]
6.
Nagasu A; Mukai T; Iseki M; Kawahara K; Tsuji S; Nagasu H; Ueki Y; Ishihara K; Kashihara N; Morita Y
Cells; 2019 Apr; 8(5):. PubMed ID: 31052273
[TBL] [Abstract][Full Text] [Related]
7. Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.
Liu L; Takeda K; Akkoyunlu M
Front Immunol; 2020; 11():1569. PubMed ID: 32849532
[TBL] [Abstract][Full Text] [Related]
8. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.
Wu Y; He S; Bai B; Zhang L; Xue L; Lin Z; Yang X; Zhu F; He P; Tang W; Zuo J
Cell Mol Immunol; 2016 May; 13(3):379-90. PubMed ID: 25942599
[TBL] [Abstract][Full Text] [Related]
10. Piperlongumine alleviates lupus nephritis in MRL-Fas(lpr) mice by regulating the frequency of Th17 and regulatory T cells.
Yao L; Chen HP; Ma Q
Immunol Lett; 2014 Sep; 161(1):76-80. PubMed ID: 24837470
[TBL] [Abstract][Full Text] [Related]
11. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
[TBL] [Abstract][Full Text] [Related]
12. IL-10 regulates murine lupus.
Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
[TBL] [Abstract][Full Text] [Related]
13. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
Bökers S; Urbat A; Daniel C; Amann K; Smith KG; Espéli M; Nitschke L
J Immunol; 2014 Apr; 192(7):2994-3002. PubMed ID: 24600033
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus.
Jin O; Zhang H; Gu Z; Zhao S; Xu T; Zhou K; Jiang B; Wang J; Zeng X; Sun L
Cell Mol Immunol; 2009 Dec; 6(6):461-7. PubMed ID: 20003822
[TBL] [Abstract][Full Text] [Related]
15. Endogenous Tim-1 promotes severe systemic autoimmunity and renal disease MRL-Fas(lpr) mice.
Nozaki Y; Kitching AR; Akiba H; Yagita H; Kinoshita K; Funauchi M; Matsumura I
Am J Physiol Renal Physiol; 2014 May; 306(10):F1210-21. PubMed ID: 24623145
[TBL] [Abstract][Full Text] [Related]
16. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.
Yasuda K; Watkins AA; Kochar GS; Wilson GE; Laskow B; Richez C; Bonegio RG; Rifkin IR
PLoS One; 2014; 9(7):e103478. PubMed ID: 25076492
[TBL] [Abstract][Full Text] [Related]
17. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
19. Regulation of T cell-dependent autoantibody production by a gammadelta T cell line derived from lupus-prone mice.
Fujii T; Okada M; Craft J
Cell Immunol; 2002; 217(1-2):23-35. PubMed ID: 12425998
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
